Associate Director, Field Medical Affairs-Thoracic Oncology and Pan-Tumor (northern CA, NV, WA, OR, AK)
Regeneron Pharmaceuticals
Summary
At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking an Associate Director, Field Medical Affairs responsible for engaging in the exchange of scientific data and other medical and/or scientific information with key opinion leaders (KOLs), health care providers (HCPs), researchers, pharmacists and population-based decision makers. We demonstrate a thorough understanding of solid tumors, including thoracic malignancies, and other tumors of interest within clinical development and aligned with our strategic medical plans.
Job description
When & where
Location: Field-northern, CA, Nevada, Idaho, Oregon, Alaska
Discover your role
- Establish, foster, cultivate and maintain peer relationships with KOLs.
- Act as the primary clinical/scientific resource to HCPs for information pertaining to disease state and our product(s) to ensure awareness and understanding.
- Identifies and maintains a list of relevant medical/therapeutic area experts, investigators and develop engagement plans.
- Support evidence generation (company sponsored trials and investigator initiated studies (IIS)) research initiatives
- Identify and report medical insights.
- Identifies gaps in research and educational needs to inform medical strategy.
- Responds to requests for information and presents/discusses scientific and clinical data to appropriate audience in a compliant manner.
- Performs disease management and therapeutic area education with identified practitioners, payers and researchers.
- Attends medical conferences to collect and report relevant, scientific, clinical, & competitive intelligence with the purpose of informing internal partners.
- Ensures company policies, procedures, principles and financial controls are maintained with integrity and professionalism is displayed internally and externally.
This role requires
- A terminal scientific degree (MD, PharmD, PhD, DNP or DVM) is required.
- 8+ years of experience with a minimum of 4 years’ experience as an Oncology Medical Science Liaison function is required.
- Knowledge or experience in the Oncology therapeutic area is required, and experience in thoracic malignancies preferred.
- Established relationships with KOLs in thoracic malignancies and knowledge of institutions focused on Solid Tumor Malignancies preferred.
- Drug launch experience is strongly preferred.
- Knowledge of treatment guidelines, clinical research processes, FDA regulations, pharma regulations/compliant practices, and OIG guidelines.
- Residency in the assigned territory and possession and maintaining a valid driver’s license and clean driving record.
Requirements
- A terminal scientific degree (MD, PharmD, PhD, DNP or DVM) is required.
- 8+ years of experience with a minimum of 4 years’ experience as an Oncology Medical Science Liaison function is required.
- Knowledge or experience in the Oncology therapeutic area is required.
- Experience in thoracic malignancies preferred.
- Established relationships with KOLs in thoracic malignancies and knowledge of institutions focused on Solid Tumor Malignancies preferred.
- Drug launch experience is strongly preferred.
- Knowledge of treatment guidelines, clinical research processes, FDA regulations, pharma regulations/compliant practices, and OIG guidelines.
- Residency in the assigned territory and possession and maintaining a valid driver’s license and clean driving record.
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.